Cart
sales@molnova.com
WH-4-023
CAS No. 837422-57-8
WH-4-023( WH-4-023 | WH4-023 | WH 4-023 | WH-4023 )
Catalog No. M16103 CAS No. 837422-57-8
WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 81 | In Stock |
|
| 2MG | 45 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 96 | In Stock |
|
| 25MG | 157 | In Stock |
|
| 50MG | 193 | In Stock |
|
| 100MG | 343 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWH-4-023
-
NoteResearch use only, not for human use.
-
Brief DescriptionWH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.
-
DescriptionWH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.
-
In Vitro——
-
In Vivo——
-
SynonymsWH-4-023 | WH4-023 | WH 4-023 | WH-4023
-
PathwayTyrosine Kinase
-
TargetSrc
-
RecptorLck| Src
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number837422-57-8
-
Formula Weight568.67
-
Molecular FormulaC32H36N6O4
-
Purity>98% (HPLC)
-
SolubilityEthanol: 6 mg/mL warmed (10.55 mM); DMSO: 12 mg/mL warmed (21.1 mM)
-
SMILESO=C(OC1=C(C)C=CC=C1C)N(C2=CC=C(OC)C=C2OC)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C3
-
Chemical Name2,6-dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Martin MW, et al. J Med Chem. 2006 Aug 10;49(16): 4981-9
molnova catalog
related products
-
Neochlorogenic acid
Chlorogenic acid has resistance to the brown rot fungus, may by interfering with fungal melanin production.
-
1-Naphthyl PP1
1-Naphthyl PP1 is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)
-
KX2-391
KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
